Glycopyrrolate (injection)

گلیکوپیرولات (تزریقی)

⚠ Unverified

🍽️ Alimentary Tract And MetabolismAnticholinergic (antimuscarinic)

Market / country: 🇺🇸 USA

Robinul (US)

🧮 Dose calculator

General anaesthesia and premedication (adjunct) · Regimen source: FDA Glycopyrrolate inj · Dosage and Administration

Enter age and weight.

🛡️ Safety & information

Contraindications

  • ⛔ Hypersensitivity; for prolonged peptic-ulcer therapy: glaucoma, obstructive uropathy, GI obstruction, paralytic ileus, intestinal atony, unstable cardiovascular status, severe ulcerative colitis, myasthenia gravis. FDA Glycopyrrolate inj · Contraindications

Warnings

Formulations

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Glycopyrrolate inj · Pregnancy

    “Teratogenic Effects Pregnancy Category B: Reproduction studies with glycopyrrolate were performed in rats at a dietary dose of approximately 65 mg/kg/day (exposure was approximately 320 times the maximum recommended daily human dose of 2 mg on a mg/m 2 basis) and rabbits at intramuscular doses of up to 0.5 mg/kg/day …”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Glycopyrrolate inj · Nursing Mothers

    “Because many drugs are excreted in human milk, caution should be exercised when glycopyrrolate injection is administered to a nursing woman.”
  • 👶 ChildrenUse with caution

    Label: paediatric pre-anaesthetic dosing (0.004 mg/kg); not in neonates under 1 month (benzyl alcohol); not established for peptic ulcer. FDA Glycopyrrolate inj · Pediatric Use

    “Due to its benzyl alcohol content, glycopyrrolate injection should not be used in neonates, i.e., patients less than 1 month of age.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Glycopyrrolate inj · Geriatric Use

    “In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other therapy.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav